4. Comparison of US and European Guidelines

5. Oral Antiplatelet Therapy in Primary PCI/STEMI

7. GP IIb/IIIa Inhibitors in Primary PCI/STEMI

8. EUROMAX Bleeding Outcomes at 30 d

9. HORIZONS-AMI Bleeding Outcomes at 30 d in a Primary PCI Population

10. CHAMPION PHOENIX Primary Efficacy Outcomes at 48 h, MITT

11. Anticoagulation in Primary PCI/STEMI

12. FUTURA/OASIS 8

13. Oral Antiplatelet Therapy in Non-ST Elevation ACS

14. CHARISMA Bleeding End Points by Baseline Daily Aspirin Dose

15. CURRENT Efficacy and Bleeding by Aspirin Dose

16. EARLY-ACS Bleeding Outcomes at 30 days

17. GP IIb/IIIa Inhibitors in Primary PCI/Non-ST-segment Elevation ACS

18. PLATO Subanalysis Efficacy and Safety End Points

19. Anticoagulation in Non-ST-segment Elevation ACS

20. OASIS 5 -- Cumulative Risk of Death, MI, or Refractory Ischemia

21. The Future for ACS Management?

22. Abbreviations

23. Abbreviations (cont)

24. References

25. References (cont)

26. References (cont)

27. References (cont)

28. References (cont)